Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/DNM2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/DNM2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/DNM2_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/DNM2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/DNM2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/DNM2_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/DNM2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/DNM2_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/DNM2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00105929 | Oral cavity | EOLP | positive regulation of lamellipodium assembly | 11/2218 | 29/18723 | 2.83e-04 | 2.70e-03 | 11 |
GO:00902872 | Oral cavity | EOLP | regulation of cellular response to growth factor stimulus | 57/2218 | 304/18723 | 2.84e-04 | 2.70e-03 | 57 |
GO:003444623 | Oral cavity | EOLP | substrate adhesion-dependent cell spreading | 26/2218 | 108/18723 | 2.90e-04 | 2.74e-03 | 26 |
GO:000717816 | Oral cavity | EOLP | transmembrane receptor protein serine/threonine kinase signaling pathway | 64/2218 | 355/18723 | 3.85e-04 | 3.46e-03 | 64 |
GO:005164822 | Oral cavity | EOLP | vesicle localization | 37/2218 | 177/18723 | 3.88e-04 | 3.48e-03 | 37 |
GO:001701514 | Oral cavity | EOLP | regulation of transforming growth factor beta receptor signaling pathway | 29/2218 | 128/18723 | 4.03e-04 | 3.58e-03 | 29 |
GO:007147924 | Oral cavity | EOLP | cellular response to ionizing radiation | 19/2218 | 72/18723 | 5.48e-04 | 4.68e-03 | 19 |
GO:006049122 | Oral cavity | EOLP | regulation of cell projection assembly | 38/2218 | 188/18723 | 6.49e-04 | 5.42e-03 | 38 |
GO:004542816 | Oral cavity | EOLP | regulation of nitric oxide biosynthetic process | 17/2218 | 62/18723 | 6.56e-04 | 5.46e-03 | 17 |
GO:004867515 | Oral cavity | EOLP | axon extension | 27/2218 | 120/18723 | 7.04e-04 | 5.78e-03 | 27 |
GO:001077016 | Oral cavity | EOLP | positive regulation of cell morphogenesis involved in differentiation | 20/2218 | 79/18723 | 7.07e-04 | 5.78e-03 | 20 |
GO:1903729 | Oral cavity | EOLP | regulation of plasma membrane organization | 7/2218 | 15/18723 | 8.78e-04 | 6.75e-03 | 7 |
GO:008016416 | Oral cavity | EOLP | regulation of nitric oxide metabolic process | 17/2218 | 64/18723 | 9.71e-04 | 7.35e-03 | 17 |
GO:012003222 | Oral cavity | EOLP | regulation of plasma membrane bounded cell projection assembly | 37/2218 | 186/18723 | 1.03e-03 | 7.64e-03 | 37 |
GO:00990035 | Oral cavity | EOLP | vesicle-mediated transport in synapse | 39/2218 | 200/18723 | 1.14e-03 | 8.29e-03 | 39 |
GO:00069093 | Oral cavity | EOLP | phagocytosis | 55/2218 | 308/18723 | 1.20e-03 | 8.65e-03 | 55 |
GO:00973201 | Oral cavity | EOLP | plasma membrane tubulation | 8/2218 | 20/18723 | 1.29e-03 | 9.17e-03 | 8 |
GO:004542913 | Oral cavity | EOLP | positive regulation of nitric oxide biosynthetic process | 12/2218 | 40/18723 | 1.71e-03 | 1.13e-02 | 12 |
GO:199013815 | Oral cavity | EOLP | neuron projection extension | 34/2218 | 172/18723 | 1.80e-03 | 1.17e-02 | 34 |
GO:007124116 | Oral cavity | EOLP | cellular response to inorganic substance | 42/2218 | 226/18723 | 2.00e-03 | 1.28e-02 | 42 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa04144 | Colorectum | AD | Endocytosis | 111/2092 | 251/8465 | 5.95e-12 | 1.42e-10 | 9.08e-11 | 111 |
hsa05100 | Colorectum | AD | Bacterial invasion of epithelial cells | 44/2092 | 77/8465 | 1.13e-09 | 2.22e-08 | 1.42e-08 | 44 |
hsa05132 | Colorectum | AD | Salmonella infection | 102/2092 | 249/8465 | 7.65e-09 | 1.28e-07 | 8.17e-08 | 102 |
hsa04666 | Colorectum | AD | Fc gamma R-mediated phagocytosis | 46/2092 | 97/8465 | 9.10e-07 | 1.22e-05 | 7.77e-06 | 46 |
hsa04961 | Colorectum | AD | Endocrine and other factor-regulated calcium reabsorption | 24/2092 | 53/8465 | 8.49e-04 | 5.93e-03 | 3.78e-03 | 24 |
hsa041441 | Colorectum | AD | Endocytosis | 111/2092 | 251/8465 | 5.95e-12 | 1.42e-10 | 9.08e-11 | 111 |
hsa051001 | Colorectum | AD | Bacterial invasion of epithelial cells | 44/2092 | 77/8465 | 1.13e-09 | 2.22e-08 | 1.42e-08 | 44 |
hsa051321 | Colorectum | AD | Salmonella infection | 102/2092 | 249/8465 | 7.65e-09 | 1.28e-07 | 8.17e-08 | 102 |
hsa046661 | Colorectum | AD | Fc gamma R-mediated phagocytosis | 46/2092 | 97/8465 | 9.10e-07 | 1.22e-05 | 7.77e-06 | 46 |
hsa049611 | Colorectum | AD | Endocrine and other factor-regulated calcium reabsorption | 24/2092 | 53/8465 | 8.49e-04 | 5.93e-03 | 3.78e-03 | 24 |
hsa051002 | Colorectum | SER | Bacterial invasion of epithelial cells | 36/1580 | 77/8465 | 1.56e-08 | 3.45e-07 | 2.50e-07 | 36 |
hsa041442 | Colorectum | SER | Endocytosis | 81/1580 | 251/8465 | 1.14e-07 | 2.36e-06 | 1.71e-06 | 81 |
hsa046662 | Colorectum | SER | Fc gamma R-mediated phagocytosis | 39/1580 | 97/8465 | 5.84e-07 | 9.70e-06 | 7.04e-06 | 39 |
hsa051322 | Colorectum | SER | Salmonella infection | 77/1580 | 249/8465 | 1.56e-06 | 2.35e-05 | 1.71e-05 | 77 |
hsa049612 | Colorectum | SER | Endocrine and other factor-regulated calcium reabsorption | 19/1580 | 53/8465 | 2.32e-03 | 1.75e-02 | 1.27e-02 | 19 |
hsa051003 | Colorectum | SER | Bacterial invasion of epithelial cells | 36/1580 | 77/8465 | 1.56e-08 | 3.45e-07 | 2.50e-07 | 36 |
hsa041443 | Colorectum | SER | Endocytosis | 81/1580 | 251/8465 | 1.14e-07 | 2.36e-06 | 1.71e-06 | 81 |
hsa046663 | Colorectum | SER | Fc gamma R-mediated phagocytosis | 39/1580 | 97/8465 | 5.84e-07 | 9.70e-06 | 7.04e-06 | 39 |
hsa051323 | Colorectum | SER | Salmonella infection | 77/1580 | 249/8465 | 1.56e-06 | 2.35e-05 | 1.71e-05 | 77 |
hsa049613 | Colorectum | SER | Endocrine and other factor-regulated calcium reabsorption | 19/1580 | 53/8465 | 2.32e-03 | 1.75e-02 | 1.27e-02 | 19 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DNM2 | SNV | Missense_Mutation | novel | c.1285N>C | p.Asp429His | p.D429H | P50570 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AC-A2QI-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cytoxan | CR |
DNM2 | SNV | Missense_Mutation | novel | c.873N>T | p.Glu291Asp | p.E291D | P50570 | protein_coding | tolerated(1) | benign(0.007) | TCGA-E9-A1RF-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD |
DNM2 | insertion | Frame_Shift_Ins | novel | c.1822_1823insTGCCCAGCCAAAACTTTTTTTATAAAAA | p.Asp608ValfsTer116 | p.D608Vfs*116 | P50570 | protein_coding | | | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
DNM2 | SNV | Missense_Mutation | novel | c.646N>A | p.Ala216Thr | p.A216T | P50570 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
DNM2 | SNV | Missense_Mutation | novel | c.2509N>T | p.Arg837Trp | p.R837W | P50570 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.639) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
DNM2 | SNV | Missense_Mutation | | c.1584N>G | p.Ile528Met | p.I528M | P50570 | protein_coding | deleterious(0.03) | possibly_damaging(0.766) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR |
DNM2 | SNV | Missense_Mutation | novel | c.766N>G | p.Arg256Gly | p.R256G | P50570 | protein_coding | deleterious(0.01) | probably_damaging(0.997) | TCGA-VS-A9UO-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
DNM2 | SNV | Missense_Mutation | novel | c.767N>C | p.Arg256Thr | p.R256T | P50570 | protein_coding | tolerated(0.06) | probably_damaging(0.997) | TCGA-VS-A9UO-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
DNM2 | SNV | Missense_Mutation | | c.886N>A | p.Leu296Ile | p.L296I | P50570 | protein_coding | tolerated(0.2) | possibly_damaging(0.823) | TCGA-A6-5661-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DNM2 | SNV | Missense_Mutation | rs749953105 | c.2170C>T | p.Arg724Cys | p.R724C | P50570 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |